NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

9 Months Ended

Jun. 30, 2020

10. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	June 30,		September 30,
	2020		2019
Accrued compensation and benefits	$	20,035	$	34,625
Accrued interest		3,707		10,830
Accrued professional fees		158,945		156,919
Accrued research and development		177,877		88,553
Other accrued expenses		74,410		114,672
Total	$	434,974	$	405,599